CareDx (CDNA) Cash & Equivalents (2013 - 2026)

CareDx has disclosed Cash & Equivalents across 14 years of filings, most recently posting $373.6 million for Q2 2026.

• In Q2 2026, Cash & Equivalents rose 447.76% year-over-year to $373.6 million; the TTM figure through Jun 2026 stood at $373.6 million (up 447.76% YoY), while the FY2025 annual figure was $65.4 million, down 42.95% from the prior year.
• Cash & Equivalents came in at $373.6 million for Q2 2026 at CareDx, up from $77.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $373.6 million in Q2 2026 to a low of $65.4 million in Q4 2025.
• Average Cash & Equivalents over 5 years is $110.9 million, with a median of $89.3 million recorded in 2022.
• Year-over-year, Cash & Equivalents slumped 76.5% in 2022 and jumped 447.76% in 2026.
• Over 5 years, Cash & Equivalents stood at $89.9 million in 2022, then dropped by 8.59% to $82.2 million in 2023, then soared by 39.53% to $114.7 million in 2024, then sank by 42.95% to $65.4 million in 2025, then soared by 471.06% to $373.6 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $373.6 million in Q2 2026, $77.9 million in Q1 2026, and $65.4 million in Q4 2025.